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Abstract
Background: The predictive accuracy of the American Joint Committee on Cancer (AJCC) stages of colorectal
cancer (CRC) is mediocre. This study aimed to develop postoperative nomograms to predict cancer-specific survival
(CSS) and overall survival (OS) after CRC resection without preoperative therapy.
Methods: Eligible patients with stage I to IV CRC (n = 56072) diagnosed from 2004 to 2010 were selected from the
Surveillance, Epidemiology, and End Results (SEER) database. The patients were allocated into training (n = 27,700),
contemporary (n = 3158), and prospective (n = 25,214) validation cohorts. Clinically important variables were
incorporated and selected using the Akaike information criterion in multivariate Cox regressions to derive
nomograms with the training cohort. The performance of the nomograms was assessed and externally testified
using the concordance index (c-index), bootstrap validation, calibration, time-dependent receiver-operating
characteristic curves, Kaplan–Meier curves, mosaic plots, and decision curve analysis (DCA). Performance of the
conventional AJCC stages was also compared with the nomograms using similar statistics.
Results: The nomograms for CSS and OS shared common predictors: sex, age, race, marital status, preoperative
carcinoembryonic antigen status, surgical extent, tumor size, location, histology, differentiation, infiltration depth,
lymph node count, lymph node ratio, and metastasis. The c-indexes of the nomograms for CSS and OS were 0.816
(95 % CI 0.810–0.822) and 0.777 (95 % CI 0.772–0.782), respectively. Performance evaluations showed that the
nomograms achieved considerable predictive accuracy, appreciable reliability, and significant clinical validity with
wide practical threshold probabilities, while the results remained reproducible when applied to the validation
cohorts. Additionally, model comparisons and DCA proved that the nomograms excelled in stratifying each AJCC
stage into three significant prognostic subgroups, allowing for more robust risk classification with an improved
net benefit.
Conclusions: We propose two prognostic nomograms that exhibit improved predictive accuracy and net benefit
for patients who have undergone CRC resection. The established nomograms are intended for risk assessment and
selection of suitable patients who may benefit from adjuvant therapy and intensified follow-up after surgery.
Independent external validations may still be required.
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Abbreviations: AIC, akaike information criterion; AJCC, American joint committee on cancer; AUC, area under the
receiver-operating characteristic curve; CEA, carcinoembryonic antigen; CI, confident interval; CRC, colorectal cancer;
CSS, cancer-specific survival; DCA, decision curve analysis; LNC, lymph node count; LNR, lymph node ratio;
OS, overall survival; ROC, receiver-operating characteristic; SEER, surveillance, epidemiology, and end results
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Background
Colorectal cancer (CRC) is a leading contributor to can-
cer mortality worldwide [1, 2]. Surgical treatment is the
mainstay for elimination of CRC and continuity of life
[3, 4]. However, patients with a high risk of postopera-
tive progression of CRC require additional interventions
and informed decision-making with the help of physi-
cians [3–5]. Among the vast spectrum of clinicopatho-
logical information [3, 6], the American Joint Committee
on Cancer (AJCC) stages of CRC are fundamental for
choosing optimal clinical interventions, and their use
remains at the forefront of predicting and treating CRC
[7]. Unfortunately, many observations are not consistent
with the assumed relationship between advanced
anatomical stages and reduced survival probabilities. For
instance, disease recurs in 25 % of patients with early
CRC who are node-negative following curative resection
[8]. Patients with stage II CRCs with low-risk features
more frequently encounter adverse events than those
with high-risk features [9]. Postoperative adjuvant ther-
apies for patients with stage II CRC with fewer than 12
recovered nodes or other risk factors have not gained a
clear survival benefit as expected [10–12]; however, a
substantial improvement in survival has been achieved
for patients with stage III CRC [11, 12]. Therapeutic
effects only partially explain the conspicuous survival
inhomogeneity within stage III CRC although stage
migrations due to inadequate pathologic assessment may
also play a role [13, 14]. Metastatic CRC after curative
hepatic resection has a 5-year overall survival (OS) of
Fig. 1 Flow diagram of patient selection and study development
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Table 1 Characteristics of patients with colorectal cancer
Variables Training cohort Validation cohort Test cohort
(n = 27700) (n = 3158) (n = 25214)
Sex, n, %
Female 14077 50.8 1605 50.8 12702 50.4
Male 13623 49.2 1553 49.2 12512 49.6
Age, year, median, range 67 18–99 67 18–99 67 18–99
Race, n, %
White 21722 78.4 2428 76.9 19710 78.2
Black 3422 12.4 412 13.0 3106 12.3
Yellow (Chinese, Korean and Japanese) 1229 4.4 169 5.4 1075 4.3
Other 1327 4.8 149 4.7 1323 5.2
Marital status at diagnosis, n, %
Married (including separated) 15900 57.4 1812 57.3 14166 56.2
Divorced 2378 8.6 266 8.4 2297 9.1
Single (never married) 3519 12.7 406 12.9 3553 14.1
Widowed 5185 18.7 601 19.1 4363 17.3
Unknown 718 2.6 73 2.3 835 3.3
CEA status, n, %
Negative 15550 56.1 1803 57.1 14824 58.8
Positive 12150 43.9 1355 42.9 10390 41.2
Tumor site, n, %
Proximal colon (cecum to splenic flexure) 14341 51.7 1621 51.3 13790 54.7
Distal colon (descending to sigmoid colon) 8015 29.0 952 30.2 7441 29.5
Overlapping lesion of colon 284 1.0 24 0.8 275 1.1
Rectum (including rectosigmoid junction) 5060 18.3 561 17.7 3708 14.7
Tumor size, n, %
≤ 5 cm 16861 60.9 1966 62.3 15178 60.2
> 5 cm 9120 32.9 998 31.6 8557 33.9
Unknown 1719 6.2 194 6.1 1479 5.9
Extent of surgery, n, %
Local/segmental resection 12879 46.5 1505 47.7 11464 45.5
Subtotal/hemisection 13991 50.5 1549 49.0 13137 52.1
Total resection 830 3.0 104 3.3 613 2.4
Histology, n, %
Adenocarcinoma 27375 98.8 3116 98.7 24975 99.1
Signet ring cell carcinoma 325 1.2 42 1.3 239 0.9
Tumor grade, n, %
Well to Moderately differentiated (G1 + G2) 21137 76.3 2435 77.1 19450 77.2
Poorly to Undifferentiated (G3 + G4) 5931 21.4 646 20.5 5202 20.6
Unknown 632 2.3 77 2.4 562 2.2
pT stage, n, %
pT1 2381 8.6 272 8.6 2662 10.6
pT2 3987 14.4 447 14.2 3844 15.2
pT3 17094 61.7 1980 62.7 14887 59.0
pT4a 2244 8.1 256 8.1 2242 8.9
pT4b 1994 7.2 203 6.4 1579 6.3
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Table 1 Characteristics of patients with colorectal cancer (Continued)
pN stage, n, %
N0 14069 50.8 1615 51.1 13378 53.1
N1a 3445 12.4 402 12.7 3005 11.9
N1b 3960 14.3 456 14.4 3378 13.4
N2a 3055 11.0 356 11.2 2611 10.4
N2b 3171 11.5 329 10.4 2842 11.2
Lymph node count, mean, sd 15.7 9.6 15.8 9.6 18.4 9.6
Lymph node ratio, mean, IQR 0.16 0–0.24 0.16 0–0.22 0.13 0–0.18
Metastasis, n, %
M0 22512 81.3 2587 81.9 21112 83.7
M1 5188 18.7 571 18.1 4102 16.3
Follow-up 63 1–107 64 1–107 34 1–59
Number of events 9341 13359 1055 1496 5659 7689
1-year cumulative survival 87.9 84.1 88.6 84.7 89.8 86.5
3-year cumulative survival 73.8 67.1 75.1 68.7 77.3 70.9
5-year cumulative survival a 66.6 57.2 67.7 58.6 70.8 60.6
aSurvival probabilities of the test cohort at 5 years were approximated at 59 months
CEA carcinoembryonic antigen, sd standard deviation, IQR interquartile range, CSS cancer-specific survival, OS overall survival
Fig. 2 Adjusted relative hazards with continuous variables. a–c The optimized number of knots applied in the multivariate analysis of CSS was 4,
6, and 3 for age, LNC, and LNR, respectively. d–f These numbers of knots were 4, 6, and 4 for the same three variables in the analysis of OS. RCS,
restricted cubic spline function; CSS, cancer-specific survival; OS, overall survival; LNC, lymph node count; LNR, lymph node ratio
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Table 2 Univariate cox regression analysis of training cohort
Variables Cancer-specific survival Overall survival
HR 95 % CI P HR 95 % CI P
Sex
Female ref ref
Male 1.060 1.018–1.104 0.0049 1.055 1.019–1.091 0.0021
Race
White ref ref
Black 1.278 1.206–1.354 <0.0001 1.157 1.101–1.216 <0.0001
Yellow (Chinese, Korean and Japanese) 0.762 0.682–0.850 <0.0001 0.701 0.638–0.770 <0.0001
Other 0.974 0.884–1.072 0.5850 0.870 0.800–0.946 0.0011
Marital status at diagnosis
Married (including separated) ref ref
Divorced 1.171 1.088–1.259 <0.0001 1.175 1.103–1.251 <0.0001
Single (never married) 1.332 1.255–1.414 <0.0001 1.316 1.250–1.386 <0.0001
Widowed 1.376 1.305–1.450 <0.0001 1.746 1.675–1.821 <0.0001
Unknown 1.045 0.914–1.196 0.5175 1.246 1.120–1.387 0.0001
CEA status
Negative ref ref
Positive 3.174 3.042–3.313 <0.0001 2.449 2.366–2.535 <0.0001
Tumor site
Proximal colon ref ref
Distal colon 0.892 0.850–0.935 <0.0001 0.835 0.803–0.869 <0.0001
Overlapping lesion of colon 1.382 1.153–1.657 0.0005 1.294 1.108–1.510 0.0011
Rectum 0.880 0.833–0.931 <0.0001 0.825 0.787–0.865 <0.0001
Tumor size
≤ 5 cm ref ref
> 5 cm 1.429 1.370–1.491 <0.0001 1.316 1.270–1.363 <0.0001
Unknown 0.821 0.746–0.904 0.0001 0.806 0.745–0.873 <0.0001
Extent of surgery
Local/segmental resection ref ref
Subtotal/hemisection 1.161 1.114–1.211 <0.0001 1.181 1.141–1.223 <0.0001
Total resection 1.527 1.373–1.699 <0.0001 1.388 1.264–1.525 <0.0001
Histology
Adenocarcinoma ref ref
Signet ring cell carcinoma 2.648 2.304–3.044 <0.0001 2.180 1.916–2.480 <0.0001
Tumor grade
G1/G2 ref ref
G3/G4 1.903 1.820–1.989 <0.0001 1.614 1.553–1.678 <0.0001
Unknown 1.007 0.871–1.164 0.9283 0.942 0.834–1.064 0.3372
pT stage
pT1 ref ref
pT2 1.854 1.556–2.209 <0.0001 1.662 1.495–1.848 <0.0001
pT3 6.161 5.285–7.182 <0.0001 3.150 2.871–1.848 <0.0001
pT4a 13.422 11.43–15.760 <0.0001 5.775 5.21–6.400 <0.0001
pT4b 17.429 14.844–20.464 <0.0001 7.324 6.607–8.120 <0.0001
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Table 2 Univariate cox regression analysis of training cohort (Continued)
Metastasis
M0 ref ref
M1 7.733 7.414–8.066 <0.0001 4.953 4.773–5.139 <0.0001
HR hazard ratio, 95 % CI 95 % confident interval, ref reference category, CEA carcinoembryonic antigen
Table 3 Multivariate cox regression analysis of training cohort
Cancer-specific survival Overall survival
Covariates HR 95 % CI P HR 95 % CI P
Sex (Male vs. Female) 1.142 1.094–1.193 <0.0001 1.246 1.202–1.293 <0.0001
Race (ref, White)
Black 1.199 1.130–1.273 <0.0001 1.191 1.132–1.254 <0.0001
Yellow (Chinese, Korean, Japanese) 0.784 0.702–0.875 <0.0001 0.713 0.649–0.784 <0.0001
Other 1.030 0.935–1.135 0.5449 0.996 0.915–1.083 0.9203
Marital status at diagnosis (ref, Married)
Divorced 1.175 1.092–1.265 <0.0001 1.214 1.139–1.293 <0.0001
Single (never married) 1.235 1.161–1.313 <0.0001 1.277 1.211–1.346 <0.0001
Widowed 1.189 1.118–1.264 <0.0001 1.224 1.165–1.285 <0.0001
Unknown 1.014 0.886–1.161 0.8424 1.145 1.029–1.275 0.0131
CEA status (Positive vs. negative) 1.589 1.517–1.664 <0.0001 1.486 1.431–1.543 <0.0001
Extent of surgery (ref, Loc/seg resection)
Subtotal/hemisection 1.067 1.012–1.125 0.0156 1.040 0.995–1.087 0.0824
Total resection 1.269 1.139–1.414 <0.0001 1.180 1.073–1.297 0.0007
Tumor site (ref, Proximal colon)
Distal colon 0.910 0.860–0.962 <0.0001 0.918 0.876–0.962 0.0004
Overlapping lesion of colon 1.090 0.909–1.307 0.3545 1.111 0.952–1.298 0.1824
Rectum 1.002 0.935–1.074 0.9516 0.981 0.926–1.040 0.5211
Tumor size (ref, ≤ 5 cm)
>5 cm 1.029 0.984–1.076 0.2050 1.026 0.989–1.066 0.1741
Unknown 1.141 1.035–1.258 0.0078 1.075 0.991–1.166 0.0810
Histology (ref, Adenocarcinoma)
Signet ring cell carcinoma 1.409 1.220–1.626 <0.0001 1.380 1.209–1.575 <0.0001
Tumor grade (ref, G1/G2)
G3/G4 1.278 1.219–1.339 <0.0001 1.184 1.137–1.233 <0.0001
Unknown 1.143 0.987–1.323 0.0736 1.049 0.927–1.186 0.4501
pT stage (ref, pT1)
pT2 1.567 1.312–1.872 <0.0001 1.398 1.254–1.558 <0.0001
pT3 2.949 2.516–3.457 <0.0001 1.796 1.628–1.981 <0.0001
pT4a 4.429 3.746–5.237 <0.0001 2.508 2.247–2.799 <0.0001
pT4b 4.760 4.021–5.634 <0.0001 2.746 2.456–3.069 <0.0001
Metastasis (M1 vs. M0) 4.075 3.876–4.284 <0.0001 3.357 3.213–3.508 <0.0001
HR hazard ratio, 95 % CI 95 % confident interval, ref reference category, Loc/seg resection Local/segmental resection, CEA carcinoembryonic antigen
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47.7 to 57.6 % [15, 16], while the OS of most patients
with unresectable metastatic CRC is extremely poor
[17]. Survival of CRC remains poor for multiple reasons
that are not limited to tumor-related factors. Despite the
increased complexity among several modifications of the
AJCC cancer staging manuals [14], the AJCC stages have
intrinsic defects as an anatomy-dependent rather than
multidiscipline-integrated metric [18]. Moreover, the
AJCC stages force categorization of tumor dissemin-
ation in a stepwise fashion, causing additional loss of
predictive accuracy [18, 19]. A consequential issue has
thus emerged: both the 5-year cancer-specific survival
(CSS) and OS are heterogeneous among patients with
the same stage of CRC [14].
Many useful factors are not sufficiently utilized in
clinical prognostication. The plasma carcinoembryonic
antigen (CEA) concentration is strongly predictive
[15, 19] and plays roles in staging other than indicat-
ing recurrence. Patient-specific factors such as sex,
ethnicity, and marital status are also associated with
Fig. 3 Nomograms for (a) CSS and (b) OS. Generally, each individual involved covariate was assessed for the patient and given a point on the basis of
the nomograms. Aggregated points were obtained by summing the given points of all involved variables. The aggregated points corresponded to
particular survival probabilities and median survival years that could be indicated by the nomograms. A higher total number of points frequently
indicated a higher possibility of adverse outcomes (CSS or OS) and therefore a lower expected survival. CSS, cancer-specific survival; OS, overall survival
Zhang et al. BMC Cancer  (2016) 16:658 Page 7 of 21
Table 4 Points for categorical variables in nomograms
Points
Variables Labels for tick marks CSS OS
Sex
Female Female 0 0
Male Male 7.5 9.2
Race
White White 13.8 14.1
Black Black 24.1 21.4
Yellow (Chinese, Korean and Japanese) Yellow 0 0
Other Other 15.5 13.9
Marital status at diagnosis
Married (including separated) Mar 0 0
Divorced Div 9.2 8.1
Single (never married) Sin 11.9 10.2
Widowed Wid 9.8 8.4
Unknown Uk 0.8 5.7
CEA status
Negative Negative 0 0
Positive Positive 26.2 16.6
Tumor site
Proximal colon (cecum to splenic flexure) Pc 5.4 3.6
Distal colon (descending to sigmoid colon) Dc 0 0
Overlapping lesion of colon Oc 10.3 8.0
Rectum (including rectosigmoid junction) Rect 5.5 2.8
Tumor size
≤5 cm 0–5 0 0
>5 cm 5+ 1.6 1.1
Unknown Uk 7.5 3.0
Extent of surgery
Local/segmental resection Loc/Seg 0 0
Subtotal/hemisection Partial 3.7 1.6
Total resection Total 13.5 6.9
Histology
Adenocarcinoma Adeno 0 0
Signet ring cell carcinoma Signet 19.4 13.5
Tumor grade
Well to Moderately differentiated (G1 + G2) G1/2 0 0
Poorly to Undifferentiated (G3 + G4) G3/4 13.9 7.1
Unknown Uk 7.6 2.0
pT stage
pT1 T1 0 0
pT2 T2 25.5 14.0
pT3 T3 61.3 24.5
pT4a T4a 84.3 38.4
pT4b T4b 88.4 42.2
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survival [1, 2, 20, 21], representing untapped information
that may be useful for individualized therapies and out-
comes. Many other parameters included in routine patho-
logic reports are also apparent survival determinants,
including tumor location, size, histology, grade, differenti-
ation, lymph node count (LNC), lymph node ratio (LNR),
and surgical extent [6]. All of these elements are insepar-
able qualities of a “successful cancer career,” of which
more detailed evaluations are still required, however.
We anticipate that the combined performance of the
above-mentioned factors is superior to that of the AJCC
stages and may serve as a more precise and reproducible
tool for individualized survival estimations. We have
herein incorporated clinically important variables with
data from the Surveillance, Epidemiology, and End
Results (SEER) database to develop validated prognostic
nomograms for predicting CSS and OS of patients with
surgically treated CRC without neoadjuvant therapies.
Methods
Patient eligibility and variables
The SEER program is a national database and primary
source of cancer statistics that is currently maintained by
the National Cancer Institute [22]. The data of patients
with CRC diagnosed from 2004 to 2010 were retrieved
from the SEER research database using the SEER*Stat
program (v 8.2.1) [22]. In total, 265,030 records were
retrieved. Any surgically treated, pathologically proven,
staged colorectal adenocarcinomas were considered. Only
patients who met the following criteria were included in
the formal analysis: (1) known preoperative CEA status,
(2) no history of malignancy, (3) microscopically proven
stage I to IV primary adenocarcinoma (including signet
ring cell carcinoma), (3) no adjuvant therapy before sur-
gery, (4) cancer-directed surgery of primary tumors with
sufficient information to specify the T/N/M stage and
LNC/LNR, (5) active follow-up with complete date and
known outcome, and (6) adequate/consistent information
to specify the primary tumor site, size, and other variables.
Patients aged <18 or >99 years and those with multiple
primary cancers were excluded. Patients were also ex-
cluded if their T/N did not meet pathological staging cri-
teria (not pT/N). These patients were small in number,
but they might have introduced bias to the survival ana-
lysis; thus, they were excluded.
The following variables were assessed: sex, age, race,
marital status, year of diagnosis, primary tumor location,
size, histology, grade, TNM stage, LNC, cause-specific
death, and vital status. Cancer stages reported using the
6th AJCC/TNM stages (AJCC6) were converted based
on the 7th edition (AJCC7). The LNR was calculated by
dividing metastatic node number by the LNC.
After patient exclusion based on the above-mentioned cri-
teria, 56,072 eligible patients were identified. Patients diag-
nosed from 2004 to 2007 were randomized into a training
cohort and a contemporary validation cohort (ratio, 90:10).
Table 4 Points for categorical variables in nomograms (Continued)
Metastasis
M0 M0 0 0
M1 M1 79.6 50.6
CSS cancer-specific survival, OS overall survival, CEA carcinoembryonic antigen
Table 5 Points for continuous variables in nomograms
Age at diagnosis Lymph node count, n Lymph node ratio
Values, no. Pts for CSS Pts for OS Values, no. Pts for CSS Pts for OS Values, % Pts for CSS Pts for OS
10 0.0 0.0 0 12.3 15.7 0 0.0 0.0
20 1.2 0.1 10 10.2 9.7 10 15.9 12.3
30 2.5 0.2 20 3.4 3.5 20 30.5 18.2
40 3.7 0.3 30 0.0 0.0 30 42.3 21.8
50 5.3 0.8 40 2.9 1.1 40 50.9 25.3
60 10.5 5.9 50 5.9 2.2 50 57.0 28.8
70 23.9 21.1 60 8.9 3.3 60 61.2 32.2
80 46.0 44.8 70 11.9 4.4 70 64.2 35.6
90 72.8 72.2 80 14.9 5.5 80 66.5 39.0
100 100.0 100.0 90 17.9 6.6 90 68.9 42.4
100 71.2 45.7
Pts points, CSS cancer-specific survival, OS overall survival
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The remaining patients were diagnosed from 2008 to 2010
and were thus assigned to a prospective test cohort (Fig. 1).
Statistical methods
Discontinuous variables were categorized before model-
ing based on clinical reasoning and significance. Linear
assumptions of continuous variables (age, LNC, and
LNR) were relaxed with restricted cubic spline functions
to determine the optimal number of knots by maximiz-
ing goodness of fit using the log-likelihood and minimiz-
ing information loss using the Akaike information
criterion (AIC) [23]. Multivariate models for nomograms
were built by incorporating significant variables from
univariate Cox proportional hazard regressions in a
backward stepwise manner based on the AIC. Model
performance was appraised using the concordance index
(c-index) and internally testified by 200-sample boot-
strap validation and calibration. External validation was
performed by applying nomograms to the contemporary
validation cohort and prospective test cohort separately,
followed by evaluation of similar statistics in the new
data sets. Different c-indexes were compared using the
compareC [24] package. Next, patients in all cohorts
were given an aggregated score using standard points
derived from the nomograms. Time-dependent receiver-
operating characteristic (ROC) curve analysis was per-
formed with the timeROC [25] package to evaluate the
performance of the nomograms with the accumulated
scores as a continuous predictive variable. The nomo-
grams were compared with the AJCC6/7 stages by risk
classification and stratification using Kaplan–Meier sur-
vival curves and statistically clarified by quantifying the
cumulative 5-year survival and hazard ratios for each
stratum. Briefly, risk classification was achieved by rank-
ing the accumulated nomogram scores by deciles to de-
rive 10 risk groups (Nomo stages) with patients in the
training cohort. For risk stratification, the patients were
divided by score tertiles for each AJCC7 substage to
generate three prognostic strata: low-, median-, and
high-risk. The two external cohorts were likewise
classified and stratified according to thresholds de-
fined by the training cohort. Next, mosaic plots were
drawn to demonstrate the AJCC7 stage distributions
in contrast with the Nomo stages. After addressing
the accuracy of the nomograms, decision curve ana-
lysis (DCA) [26] was performed to finalize the ranges
Fig. 4 Bootstrap calibrations of nomograms. The predicted 3- and 5-year (a, b) CSS and (c, d) OS were well correlated with the actual survival probabilities
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of threshold probabilities within which the nomo-
grams were clinically valuable. The patients were ran-
domly allocated using the PASW 18.0 program (SPSS
Inc., Chicago, IL); the other analyses were processed
with the R program (v 3.2.3) using rms [23] and the
above-mentioned packages. Only a two-tailed P value
of <0.05 was considered statistically significant. This
study followed the TRIPOD statement [27] and
adhered to the Declaration of Helsinki for medical re-
search involving human subjects [28].
Results
Baseline characteristics
The characteristics of the patients in the derivation and
validation cohorts are shown in Table 1.
Fig. 5 Bootstrap calibration of nomograms in the external cohorts. The nomograms were externally calibrated in the validation cohort by predicting
the 3- and 5-year (a, b) CSS and (c, d) OS. The nomograms were also calibrated in the test cohort for the 3-year (e) CSS and (f) OS. All results showed
good validation. CSS, cancer-specific survival; OS, overall survival
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Cox regression of training cohort
No continuous variables (age, LNC, or LNR) had linear ef-
fects on either CSS or OS (Fig. 2). All variables assessed in
the univariate analysis (Table 2) remained significant in the
multivariate Cox regressions except tumor size (Table 3).
Nomograms for CSS and OS
As selected by the AIC, all tested covariates were
employed in the nomograms. The c-indexes were 0.816
(95 % CI 0.810–0.822) and 0.777 (95 % CI 0.772–0.782)
for the CSS (Fig. 3a) and OS (Fig. 3b) predictive nomo-
grams, respectively. Details of the nomograms’ labels
and points were shown in Table 4 and Table 5.
Internal validation
The bootstrap-corrected c-indexes (CSS, 0.8157; OS,
0.7768) were close to those of the nomograms. Both
models exhibited good validation.
Table 6 Time-dependent receiver-operating characteristic curves analysis
Cancer-specific survival Overall survival
AUC, % AUC, %
Study cohort 1 year 3 years 5 years 7 years 1 year 3 years 5 years 7 years
Training cohort 85.2 87.6 87.5 86.6 82.1 84.1 84.2 83.6
Validation cohort 83.0 87.1 86.7 85.5 80.6 83.7 83.7 82.7
Test cohort 86.0 87.8 / / 83.1 84.6 / /
AUC area under the time-dependent receiver-operating characteristic curves
Table 7 Comparison of nomogram with AJCC staging system
Nomogram score 7th AJCC stage 6th AJCC stage P
Training cohort, CSS
AIC 172262 174703 174949 /
Log-likelihood −86130 −87344 −87468 All <0.0001
C-index (95 % CI) 0.816 (0.810–0.822) 0.777 (0.771–0.783) 0.774 (0.768–0.780) All <0.0001
Training cohort, OS
AIC 250348 255973 256182 /
Log-likelihood −125173 −127979 −128085 All <0.0001
C-index (95 % CI) 0.777 (0.772–0.782) 0.698 (0.693–0.0.703) 0.696 (0.691–0.701) All <0.0001
Validation cohort, CSS
AIC 14983 15261 15272 /
Log-likelihooda −7490 −7623 −7630 All <0.0001
C-indexb (95 % CI) 0.809 (0.791–0.827) 0.770 (0.752–0.788) 0.768 (0.750–0.786) All <0.0001
Validation cohort, OS
AIC 21611 22235 22244 /
Log-likelihoodc −10805 −11110 −11116 All <0.0001
C-indexd (95 % CI) 0.773 (0.757–0.789) 0.699 (0.683–0.715) 0.697 (0.681–0.713) All <0.0001
Test cohort, CSS
AIC 102103 104057 105039 /
Log-likelihood −51050 −52021 −52519 All <0.0001
C-index (95 % CI) 0.838 (0.830–0.846) 0.794 (0.786–0.802) 0.786 (0.778–0.794) All <0.0001
Test cohort, OS
AIC 141606 145343 146456 /
Log-likelihood −70802 −72664 −73227 All <0.0001
C-index (95 % CI) 0.802 (0.796–0.808) 0.723 (0.717–0.729) 0.715 (0.709–0.721) All <0.0001
AJCC American joint committee on cancer, AIC akaike information criterion, C-index concordance index, 95 % CI 95 % confident interval
aThe P value comparing 6th and 7th AJCC stage was 0.0003
bThe P value comparing 6th and 7th AJCC stage was 0.5187
cThe P value comparing 6th and 7th AJCC stage was 0.0006
dThe P value comparing 6th and 7th AJCC stage was 0.3709
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Nomogram calibration
As shown in the calibration plots, the nomogram-
predicted 3- and 5-year CSS and OS were well correlated
with the corresponding Kaplan–Meier estimates (Fig. 4),
suggesting appreciable reliability of the nomograms.
External validation
The c-indexes of the nomograms for prediction of CSS
and OS were 0.809 (95 % CI 0.791–0.827) and 0.773
(95 % CI 0.757–0.789) in the validation cohort, while the
optimism-corrected c-indexes were 0.804 and 0.768, re-
spectively. In the test cohort, the c-indexes were 0.839
(95 % CI 0.830–0.846) and 0.802 (95 % CI 0.796–0.808)
with corrected estimates of 0.838 and 0.801 for CSS and
OS prediction, respectively. The external calibration
plots also showed good validation (Fig. 5).
Time-dependent ROC curve analysis
The areas under the ROC curve (AUCs) for predicting
CSS ranged from 83.0 to 87.8 % in the three cohorts
from 1 to 7 years. The AUCs for predicting OS varied
from 80.6 to 84.6 % during the same years (Table 6).
The nomograms exhibited considerable efficiency to
discriminate outcomes.
Comparison of nomograms with AJCC stages
First, when compared with the AJCC6/7 stages, the nomo-
grams yielded the largest log-likelihoods and c-indexes
Fig. 6 Kaplan–Meier curve analysis of risk classification and stratification in the training cohort. a Risk classification of CSS and OS using the 7th
edition of the AJCC stages (AJCC7) and Nomo stages (all log-rank P values for trend <0.0001). b Risk stratification of CSS for each AJCC7 substage.
c Risk stratification of OS for each AJCC7 substage (all log-rank P values for trend <0.0001, all log-rank P values for pairwise comparisons <0.05).
CSS, cancer-specific survival; OS, overall survival; AJCC, American Joint Committee on Cancer
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along with the smallest AIC values for CSS and OS predic-
tion in all cohorts (Table 7). These results imply that the
nomograms were more robust than the AJCC stages.
Second, as depicted by the Kaplan–Meier curves, the
ability of the AJCC7 stages to discriminate CSS and OS
was mediocre in both the training (Fig. 6a) and external
cohorts (Fig. 7). However, the Nomo stages performed
consistently much better in all cohorts (Figs. 6a and 7).
Further analysis in the training (Fig. 6b and c) and test
cohorts (Fig. 8) showed that the nomograms were also
able to stratify each AJCC7 stage into three significant
prognostic groups with low, medium, and high risks of
CSS and OS, respectively. Additional elaborations on the
5-year cumulative survival (Table 8) and hazard ratios
(Table 9) of the Nomo stages as well as the stratified risk
groups (Table 10) confirmed robust utility of nomo-
grams in both risk classification and stratification.
Finally, the mosaic plots demonstrated significant sur-
vival heterogeneity within individual AJCC7 substages in
contrast to the Nomo stages (Fig. 9). The results offer
direct evidence and the underlying frequencies of staging
errors in the conventional AJCC staging system.
Decision curve analysis
After addressing the model accuracy, DCA was applied
to render clinical validity to the nomograms in the deriv-
ation cohort and generalize it to the external cohorts.
The results corroborated good clinical applicability of
the nomograms in predicting survival of patients with
CRC because their ranges of threshold probabilities were
wide and practical in all cohorts (Fig. 10). Additional
comparisons of model competence were also in favor of
the nomograms’ superiority over the conventional AJCC
stages because the net benefit for the patients was con-
sistently enhanced (higher lines for model prediction
relative to the horizontal lines) when using the nomo-
grams compared with using the TNM stages (Fig. 10).
Discussion
In the present study, we developed two postoperative
nomograms to predict CSS and OS for patients who
have undergone CRC resection without neoadjuvant
therapy. The nomograms consistently achieved consider-
able predictive accuracy and appreciable reliability and
reproducibility when applied to the derivation and valid-
ation cohorts. DCA subsequently demonstrated signifi-
cant clinical applicability of the nomograms with wide
threshold probabilities. In addition, model comparisons
and DCA proved that the nomograms outperformed the
conventional AJCC stages by stratifying them into three
significant prognostic groups and allowing for more ro-
bust risk classification (Nomo stages) with an improved
net benefit.
Prognostic nomograms are simplified representations
of complicated statistical models with elegant graphics
[18, 29, 30]. Compared with other predictive models,
they are more accurate and comprehensible with user-
friendly interfaces, allowing for wide application in clin-
ical practice [18, 29, 30]. A recent systematic review
summarized the basic characteristics of more than 16
Fig. 7 Kaplan–Meier curve analysis for risk classification of (a) CSS and (b) OS in the validation and test cohorts. All log-rank P values for trend <0.0001.
CSS, cancer-specific survival; OS, overall survival
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predictive nomograms for CRC [31]. Although patient
definitions, endpoints, and time points are markedly het-
erogeneous, most of the nomograms have demonstrated
improved accuracy. Our study shows some distinctions
from those published nomograms, however.
First, no previous studies incorporated both patients
with non-metastatic CRC and those with metastatic
CRC. Because both non-metastatic and metastatic CRC
are continuous representations of systemic tumor biol-
ogy, exclusion of patients with metastasis may inherit
the limitations of the AJCC stages. Second, we used
population-based data to derive nomograms for CRC;
this may be considered an update and extension of a
previously published nomogram that also used SEER
data but concentrated on curative stage I to III colonic
adenocarcinomas [32]. Population-based data often fail
to include detailed data and novel markers such as the
CEA concentration [19] and microRNAs [33], which
may be helpful to increase model accuracy. However,
population-based data are more likely to overcome
inconsistency biased by institutional practice [18]. Third,
we selected covariates based on the AIC instead of
statistical significance (P value), allowing for confidence
in the robustness of modeling and performance [34].
The P values depend not only on the magnitude of the
predictors’ effects but also on the sample size. Small data
sets are less likely to discriminate small differences, and
their use makes it more difficult to reject the null hy-
pothesis. We also used restricted cubic spline functions
for continuous variables to avoid unnecessary informa-
tion loss caused by categorization [23]. Finally, we intro-
duced DCA and proved the clinical validity of our
nomograms. High predictive accuracy is not necessarily
associated with usefulness in clinical practice. Well-
performing models may have limited applicability if the
threshold probabilities of the net benefits are impracti-
cal, meaning that the new predictive models will be less
beneficial than currently available tools and may even be
harmful [18, 26].
Our study also produced some novel findings besides
the many results consistent with previous studies. Above
all, based on the nomograms, we have proposed Nomo
stages and efficiently classified stage I to IV CRCs into
10 significant subgroups with a single predictive score.
Fig. 8 Kaplan–Meier curve analysis for risk stratification of (a) CSS and (b) OS within each AJCC substage using the test cohort. All log-rank P values for
trend <0.0001. CSS, cancer-specific survival; OS, overall survival
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Table 8 Cumulative survival for Nomo stages in derivation and external validation cohorts
Training cohort Validation cohort Test cohort
(Cumulative survival, 60 months, %) (Cumulative survival, 60 months, %) (Cumulative survival, 59 months, %)
Nomo stage CSS 95 % CI OS 95 % CI CSS 95 % CI OS 95 % CI CSS 95 % CI OS 95 % CI
Nomo 1 96.8 96.1–97.4 94.6 93.7–95.4 97.7 96.1–99.4 95.5 93.2–97.8 94.3 88.7–99.8 90.8 85.5–96.1
Nomo 2 94.0 93.1–95.0 88.1 86.9–89.3 92.9 90.0–95.8 87.1 83.4–90.9 94.0 91.5–96.6 89.0 86.5–91.4
Nomo 3 90.9 89.8–92.0 83.7 82.4–85.1 91.2 88.0–94.4 86.6 82.8–90.3 92.1 90.5–93.6 85.5 83.4–87.7
Nomo 4 87.1 85.8–88.4 76.1 74.5–77.7 88.1 84.4–91.7 78.9 74.4–83.4 87.4 84.5–90.3 76.5 73.5–79.5
Nomo 5 82.0 80.4–83.5 70.3 68.6–72.0 82.3 77.9–86.7 67.8 62.6–73.0 83.7 81.8–85.7 69.1 62.1–76.1
Nomo 6 74.2 72.4–75.9 59.0 57.2–60.9 73.6 68.5–78.7 59.4 54.0–64.8 76.1 73.9–78.4 60.1 56.9–63.3
Nomo 7 63.3 61.4–65.2 44.8 42.9–46.7 61.3 55.6–67.0 50.6 45.1–56.1 64.4 60.3–68.6 47.4 43.3–51.5
Nomo 8 43.6 41.6–45.6 32.6 30.9–34.4 50.8 44.8–56.8 32.7 27.5–37.9 49.9 46.9–53.0 31.8 27.9–35.7
Nomo 9 22.1 20.4–23.7 18.0 16.5–19.4 23.9 18.8–29.0 20.2 15.8–24.7 20.2 16.0–24.4 17.8 15.0–20.6
Nomo 10 5.7 4.7–6.6 4.8 4.0–5.6 8.4 5.2–11.6 7.3 4.5–10.2 6.3 3.9–8.6 3.8 1.3–6.3
Plog-rank for trend <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
CSS cancer-specific survival, OS overall survival, Nomo Nomo stages
Table 9 Relative hazard for Nomo stages in derivation and external validation cohorts
Training cohort Validation cohort Test cohort
Nomo stages Cut-off Points HR 95 % CI P HR 95 % CI P HR 95 % CI P
Cancer-specific survival
Nomo 1 ≤82.0 ref ref ref
Nomo 2 ≤106.2 1.86 1.48–2.35 <0.0001 2.40 1.19–4.84 0.0147 1.92 1.37–2.70 0.0002
Nomo 3 ≤122.9 2.86 2.30–3.55 <0.0001 3.33 1.70–6.51 0.0004 3.38 2.48–4.62 <0.0001
Nomo 4 ≤138.2 3.91 3.17–4.82 <0.0001 4.83 2.54–9.22 <0.0001 5.13 3.81–6.91 <0.0001
Nomo 5 ≤153.0 5.58 4.55–6.84 <0.0001 6.60 3.50–12.42 <0.0001 7.87 5.89–10.51 <0.0001
Nomo 6 ≤170.7 8.47 6.95–10.33 <0.0001 10.41 5.60–19.32 <0.0001 12.17 9.19–16.13 <0.0001
Nomo 7 ≤192.2 12.46 10.25–15.14 <0.0001 16.23 8.84–29.81 <0.0001 18.39 13.91–24.3 <0.0001
Nomo 8 ≤225.6 22.40 18.49–27.13 <0.0001 21.11 11.53–38.67 <0.0001 32.19 24.47–42.34 <0.0001
Nomo 9 ≤272.1 40.47 33.46–48.94 <0.0001 42.87 23.56–78.00 <0.0001 65.32 49.79–85.68 <0.0001
Nomo 10 272.1+ 83.31 68.9–100.73 <0.0001 86.07 47.39–156.31 <0.0001 127.46 97.2–167.12 <0.0001
Overall survival
Nomo 1 ≤57.2 ref ref ref
Nomo 2 ≤70.0 2.16 1.83–2.56 <0.0001 1.96 1.19–3.22 0.0078 2.13 1.68–2.70 <0.0001
Nomo 3 ≤80.8 3.04 2.59–3.58 <0.0001 2.63 1.64–4.21 0.0001 3.12 2.49–3.92 <0.0001
Nomo 4 ≤90.7 4.76 4.08–5.56 <0.0001 4.28 2.73–6.71 <0.0001 5.55 4.48–6.87 <0.0001
Nomo 5 ≤101.6 6.12 5.26–7.12 <0.0001 6.17 3.99–9.55 <0.0001 6.90 5.59–8.52 <0.0001
Nomo 6 ≤114.2 9.01 7.76–10.45 <0.0001 8.41 5.47–12.92 <0.0001 11.11 9.06–13.63 <0.0001
Nomo 7 ≤129.1 13.46 11.62–15.58 <0.0001 11.25 7.36–17.19 <0.0001 15.23 12.45–18.62 <0.0001
Nomo 8 ≤147.1 18.68 16.15–21.61 <0.0001 16.81 11.04–25.61 <0.0001 24.23 19.85–29.57 <0.0001
Nomo 9 ≤171.8 28.44 24.61–32.88 <0.0001 25.47 16.76–38.68 <0.0001 37.66 30.91–45.89 <0.0001
Nomo 10 171.8+ 55.25 47.8–63.86 <0.0001 45.27 29.80–68.76 <0.0001 75.07 61.63–91.45 <0.0001
HR hazard ratio, 95 % CI 95 % confident interval
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Table 10 Risk stratifications for each AJCC substage in training and test cohorts
Training cohort Test cohort
AJCC stages Cut-off Points Cumulative Survival,
60 months, %
HR 95 % CI Pairwise Plog-rank HR 95 % CI Pairwise Plog-rank
Cancer-specific survival
Stage I
Low risk group (L) ≤70.0 97.7 ref L v M < 0.0001 ref L v M < 0.0205
Median risk group (M) ≤97.2 94.4 2.44 1.91–3.13 L v H < 0.0001 1.75 1.24–2.45 L v H < 0.0001
High risk group (H) 97.2+ 88.4 4.73 3.66–6.12 M v H < 0.0001 6.12 4.27–8.77 M v H < 0.0001
Stage IIA
Low risk group (L) ≤122.7 93.9 ref L v M < 0.0001 ref L v M < 0.0001
Median risk group (M) ≤149.4 87.7 1.90 1.64–2.19 L v H < 0.0001 2.11 1.4–2.58 L v H < 0.0001
High risk group (H) 149.4+ 76.2 3.96 3.41–4.61 M v H < 0.0001 4.66 3.80–5.72 M v H < 0.0001
Stage IIB
Low risk group (L) ≤151.2 84.4 ref L v M = 0.0046 ref L v M = 0.0220
Median risk group (M) ≤178.4 71.1 1.84 1.28–2.64 L v H < 0.0001 2.09 1.29–3.39 L v H < 0.0001
High risk group (H) 178.4+ 54.1 3.30 2.22–4.90 M v H < 0.0012 5.27 3.16–8.81 M v H < 0.0001
Stage IIC
Low risk group (L) ≤158.0 76.7 ref L v M = 0.0121 ref L v M = 0.6571
Median risk group (M) ≤181.8 62.3 1.64 1.16–2.31 L v H < 0.0001 1.12 0.72–1.74 L v H < 0.0001
High risk group (H) 181.8+ 45.6 2.79 1.93–2.03 M v H < 0.0020 2.73 1.68–4.42 M v H < 0.0001
Stage IIIA
Low risk group (L) ≤88.9 94.8 ref L v M = 0.0116 ref L v M < 0.0210
Median risk group (M) ≤120.2 91.6 2.04 1.39–2.99 L v H < 0.0001 2.51 1.36–4.63 L v H < 0.0001
High risk group (H) 120.2+ 75.6 6.84 4.57–10.24 M v H < 0.0001 6.54 3.20–13.35 M v H = 0.0015
Stage IIIB
Low risk group (L) ≤147.6 85.9 ref L v M < 0.0001 ref L v M < 0.0001
Median risk group (M) ≤180.3 72.1 2.09 1.89–2.32 L v H < 0.0001 2.35 2.04–2.70 L v H < 0.0001
High risk group (H) 180.3+ 50.1 4.25 3.80–4.76 M v H < 0.0001 5.34 4.55–2.67 M v H < 0.0001
Stage IIIC
Low risk group (L) ≤187.2 65.1 ref L v M < 0.0001 ref L v M < 0.0001
Median risk group (M) ≤218.0 41.6 1.99 1.74–2.27 L v H < 0.0001 2.01 1.72–2.36 L v H < 0.0001
High risk group (H) 218.0+ 24.8 3.49 3.01–4.04 M v H < 0.0001 4.05 3.39–4.84 M v H < 0.0001
Stage IV
Low risk group (L) ≤255.6 26.2 ref L v M < 0.0001 ref L v M < 0.0001
Median risk group (M) ≤292.1 12.0 1.56 1.46–1.67 L v H < 0.0001 1.85 1.70–2.01 L v H < 0.0001
High risk group (H) 292.1+ 4.0 2.78 2.57–3.01 M v H < 0.0001 3.34 3.20–3.70 M v H < 0.0001
Overall survival
Stage I
Low risk group (L) ≤55.1 94.6 ref L v M < 0.0001 ref L v M < 0.0001
Median risk group (M) ≤79.9 84.5 2.94 2.58–3.35 L v H < 0.0001 3.10 2.58–3.72 L v H < 0.0001
High risk group (H) 79.9+ 63.1 9.07 7.90–10.41 M v H < 0.0001 10.70 8.80–13.01 M v H < 0.0001
Stage IIA
Low risk group (L) ≤75.9 90.6 ref L v M < 0.0001 ref L v M < 0.0001
Median risk group (M) ≤101.4 77.0 2.66 2.42–2.91 L v H < 0.0001 2.86 2.50–3.28 L v H < 0.0001
High risk group (H) 101.4+ 49.1 7.38 6.68–8.15 M v H < 0.0001 7.80 6.77–8.97 M v H < 0.0001
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Our nomograms also enable stratification of each AJCC7
substage into three significant risk strata, which has not
been achieved by other CRC nomograms. This risk
classification and stratification may be very useful for cli-
nicians to identify postoperative patients with high risks
associated with intensified follow-up (i.e., patients with
high-risk stage I CRC) and select less heterogeneous pa-
tients for clinical trials (i.e., patients with high-risk stage
II CRC). This also helps to understand the degree of sur-
vival heterogeneity in the AJCC stages, which frequently
introduces confusion and uncertainty to patient consult-
ing. Note that the optimal thresholds for risk classifica-
tion and stratification may be individualized, although
the thresholds defined by the training cohort still
worked well in our external cohorts, which are only
intended for relatively strict validation. Additionally and
importantly, the sharing of similar contributing predic-
tors is a reflection of apparent correlations between CSS
and OS. Some of these predictors are worth noting here.
In our models, age had a persistent effect but multiplied
from beyond 60 years old. Age is a traditional reference
for physical condition, frequency and efficiency of
reinforced therapies, thus exerts an accumulated effect
on survival. It is reasonable to presume that certain
tumor-related factors such as infiltration depth, metasta-
sis, histology, LNR, and LNC are relatively more import-
ant predictors than age. They are typical features of
tumor development and are closely related to patient
death at various but statistically significant levels. The
LNC is one of the most controversial among these
tumor-related factors. It has been proposed as a quality
indicator [6, 35] and is augmented in extended lymphad-
enectomy, the relevant long-term benefit of which has
not been effectively demonstrated because of the ab-
sence of prospective clinical trials of extended colonic
surgeries [35, 36]. Inadequate LNC assessment is in-
volved in interpretation of stage migration, which is con-
sidered a source of survival heterogeneity in patients
with CRC, but its influences are limited [14, 35, 36]. Sev-
eral previous studies classified patients by the 12-node
benchmark to derive high- and low-risk subpopulations
but achieved inconsistent results, while our results indi-
cate that such classification might be associated with a
risk of dichotomizing complex, non-linear effects of
LNC on patient survival [37]. Moreover, our analyses
indicated that LNC was less superior to LNR, which
Table 10 Risk stratifications for each AJCC substage in training and test cohorts (Continued)
Stage IIB
Low risk group (L) ≤93.5 80.3 ref L v M = 0.0007 ref L v M < 0.0001
Median risk group (M) ≤120.4 64.7 1.86 1.40–2.45 L v H < 0.0001 3.86 2.60–5.72 L v H < 0.0001
High risk group (H) 120.4+ 26.8 5.48 4.00–7.49 M v H < 0.0001 8.03 5.27–12.22 M v H < 0.0001
Stage IIC
Low risk group (L) ≤96.9 73.6 ref L v M < 0.0001 ref L v M = 0.2111
Median risk group (M) ≤121.9 54.4 2.09 1.56–2.80 L v H < 0.0001 1.35 0.92–1.98 L v H < 0.0001
High risk group (H) 121.9+ 35.5 3.54 2.58–4.86 M v H = 0.0002 3.81 2.46–5.91 M v H < 0.0001
Stage IIIA
Low risk group (L) ≤60.0 94.6 ref L v M < 0.0001 ref L v M < 0.0316
Median risk group (M) ≤90.4 84.3 3.67 2.76–4.87 L v H < 0.0001 2.10 1.36–3.25 L v H < 0.0001
High risk group (H) 90.4+ 59.4 11.71 8.66–15.84 M v H < 0.0001 9.07 5.70–14.45 M v H < 0.0001
Stage IIIB
Low risk group (L) ≤91.0 82.3 ref L v M < 0.0001 ref L v M < 0.0001
Median risk group (M) ≤116.9 63.7 2.28 2.09–2.48 L v H < 0.0001 2.72 2.42–3.07 L v H < 0.0001
High risk group (H) 116.9+ 36.6 5.06 4.60–5.56 M v H < 0.0001 6.55 5.75–7.47 M v H < 0.0001
Stage IIIC
Low risk group (L) ≤110.6 63.3 ref L v M < 0.0001 ref L v M < 0.0001
Median risk group (M) ≤137.0 35.7 2.10 1.86–2.37 L v H < 0.0001 1.94 1.68–2.24 L v H < 0.0001
High risk group (H) 137.0+ 18.2 3.97 3.47–4.55 M v H < 0.0001 4.33 3.68–5.11 M v H < 0.0001
Stage IV
Low risk group (L) ≤157.2 24.2 ref L v M < 0.0001 ref L v M < 0.0001
Median risk group (M) ≤183.3 9.9 1.59 1.49–1.69 L v H < 0.0001 1.87 1.73–2.03 L v H < 0.0001
High risk group (H) 183.3+ 3.0 2.79 2.58–3.01 M v H < 0.0001 3.51 3.19–3.88 M v H < 0.0001
AJCC American joint committee on cancer, HR hazard ratio, 95 % CI 95 % confident interval, L low risk group, M median risk group, H high risk group
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explains the reduced survival in the patient subset with
limited numbers of metastatic nodes. Additionally, the
preoperative CEA concentration provides a baseline
quantification of the tumor burden and severity of dis-
ease. The CEA concentration, with its individualized in-
formation and wide application, is due to play a role in
the staging of CRC. Next, the effects of racial back-
ground may be multifactorial. The lowest prevalence
and mortality of CRC are seen in East Asians because of
the low prevalence of risk factors such as smoking and
obesity in this population [1, 2]. The highest incidence
and mortality are seen in black people [2]; this can be
ascribed to the lower income, later diagnosis, and less
access to high-quality health care in this population [2,
20]. Additionally, marriage makes a prognostic difference
[20] and deserves more attention because it may provide
compensative mechanisms for improvements in survival.
Marital status and ethnicity were introduced to prognos-
tic nomograms for CRC for the first time in the present
study. It should also be noted that the nomogram points
translated from the models’ coefficients reflect the im-
portance of the variables relative to the presence of the
other covariates. They may vary depending on the out-
comes measured. Due to the existence of competing
risks, the predictive accuracy for OS tended to be lower
than that for CSS in our study. However, we chose a
Cox proportional hazard model without competing
risks because it was easier to interpret, compare, and
comprehend [38].
Our study has limitations that deserve attention. Im-
proved model accuracy frequently comes at the cost of
increased complexity. The tradeoffs between compre-
hensiveness and comprehensibility are not easy to bal-
ance, and this is a common problem during modeling
for nomograms. Considering this, we only selected vari-
ables that were clinically important and practical with
high reproducibility and low time-varying effects. The
nomogram itself is associated with uncertainty. There-
fore, we provided 95 % CIs for the c-indexes and calibra-
tions to determine the degree of uncertainty. Because of
the shorter follow-up, the c-indexes were slightly higher
in the test cohort than in the derivation cohort. How-
ever, the time-dependent ROC showed that the predict-
ive AUCs of the nomograms in different cohorts were
very close in the same years. Moreover, our nomograms
were developed for risk assessment and selection of pa-
tients who might benefit from additional interventions
after surgery. These interventions may include but are
not restricted to adjuvant therapies, strengthened treat-
ments, intensified follow-ups, and motivated patient
consulting. Even so, nomograms cannot substitute for
clinicians’ judgments or act as exclusive evidence for
clinical decision-making. Finally, details regarding tumor
deposit, curability of stage IV CRC, and postoperative
chemoradiotherapy among the patients in the present
study are unknown, placing a limitation on the survival
analysis. Incorporation of the new predictors and intro-
duction of competing risk models may further improve
Fig. 9 Mosaic plots using the training cohort. a CSS, b OS. In the mosaic plots, each of the 10 deciles is represented by 1 of 10 consecutive
rainbow colors. The area of the individual mosaics represents the relative frequency associated with the column cell. The short segmented lines
indicate a frequency of zero. CSS, cancer-specific survival; OS, overall survival; AJCC, American Joint Committee on Cancer
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model performance [18, 29]. However, this will require
new nomograms with different modeling strategies.
Conclusions
In the present study, the bootstrap-corrected and pro-
spectively validated nomograms were consistently reliable
and clinically practical with wide threshold probabilities.
Moreover, the nomograms outperformed the conventional
AJCC stages by allowing for more robust risk classification
and stratifying the AJCC stages with an improved net
benefit. However, independent external validations are still
required in the future.
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year OS in the training cohort. Cyan horizontal lines represent the assumption that events occurred in no patient within a particular timespan. Red lines
represent the assumption that events occurred in all patients within the same timespan. Blue lines represent the net benefit of model prediction. The
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computed by addition of the benefit (true positive) and subtraction of the harm (false positive). g, h Note that the red “assume all” lines overlap and
appear to be a single line for both the nomogram and the 6th- and 7th-version AJCC stages prediction. This occurred because they were constructed
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